CELLINK Investor Presentation 2021

CELLINK presented its bioconvergence strategy addressing modern healthcare challenges including high drug development costs, high clinical trial failure rates, and organ transplant shortages. The presentation highlights how the company's technology addresses limitations in traditional drug development and organ availability.